Please assess the completion status of the following clinical trial:

Trial Title: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced solid tumors or relapses/refractory non-Hodgkin's lymphoma confirmed by histology or cytology~* Has at least one measurable lesion (solid tumor according to RECIST v1.1 criteria, non-Hodgkin's lymphoma according to Lugnao criteria)~* ECOG score of 0 or 1;~* Expected survival time ≥ 3 months (at the discretion of the investigator);~* Adequate organ and bone marrow function;~* Voluntarily sign the informed consent form;~Exclusion Criteria:~* Has central nervous system primary malignant tumor, active epileptic seizure, spinal cord compression or carcinomatous meningitis~* The previous anti-tumor treatment has not passed the prescribed washout period~* HIV antibody is positive, or with other acquired/congenital immunodeficiency disease, or with history of organ transplantation;~* Active hepatitis B or hepatitis C virus (HCV) antibody was positive;~* Patients who are pregnant or lactating;~* Known or suspected hypersensitivity to the study drug or its pharmaceutical excipients (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol, polysorbate, arginine, succinic acid);~* Any active autoimmune disease, or known history of autoimmune disease, or syndrome requiring systemic steroids or immunosuppressive medications (other than controlled thyroid disease with alternative therapy/non-immunosuppressive therapy);~* Participation in another therapeutic or interventional clinical study in the meantime;~* Other circumstances where the investigator considers it is not appropriate to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ADG106 combined with PD-1 antibody Dose Escalation Level 1 (Type: EXPERIMENTAL): None
- ADG106 combined with anti PD-1 antibody Dose Escalation Level 2 (Type: EXPERIMENTAL): None
- ADG106 combined with anti PD-1 antibody Expansion Phase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).